April 26, 2017 7:12 AM EDT Initial Data from Global Phase 2 Program Expected Mid-2017 CAMBRIDGE, Mass.–(BUSINESS WIRE)– Ra Pharmaceuticals, Inc. (NASDAQ: RARX) today announced that it has initiated dosing in the Companys global Phase 2 clinical program evaluating RA101495 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Ra Pharma is a clinical stage biopharmaceutical company